SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001640455-20-000112
Filing Date
2020-09-01
Accepted
2020-09-01 08:38:00
Documents
17
Period of Report
2020-08-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K jnce-20200831.htm   iXBRL 8-K 57005
2 EX-99.1 jnce09012020exhibit991.htm EX-99.1 24938
8 gild11.jpg GRAPHIC 9783
9 jounceheader11.jpg GRAPHIC 45197
  Complete submission text file 0001640455-20-000112.txt   314113

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20200831.xsd EX-101.SCH 2424
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT jnce-20200831_cal.xml EX-101.CAL 714
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT jnce-20200831_def.xml EX-101.DEF 1651
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20200831_lab.xml EX-101.LAB 24975
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20200831_pre.xml EX-101.PRE 13191
10 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20200831_htm.xml XML 11511
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37998 | Film No.: 201153358
SIC: 2836 Biological Products, (No Diagnostic Substances)